TY - JOUR T1 - Efficacy of Ramucirumab <em>Versus</em> Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 2187 LP - 2192 DO - 10.21873/anticanres.14993 VL - 41 IS - 4 AU - KAZUKI MAESAKA AU - RYOTARO SAKAMORI AU - RYOKO YAMADA AU - YUKI TAHATA AU - KAZUYOSHI OHKAWA AU - MASAHIDE OSHITA AU - SHINJI TAMURA AU - HIDEKI HAGIWARA AU - EIJI MITA AU - TAKAYUKI YAKUSHIJIN AU - MASAMI INADA AU - TAKAHIRO KODAMA AU - HAYATO HIKITA AU - TOMOHIDE TATSUMI AU - TETSUO TAKEHARA Y1 - 2021/04/01 UR - http://ar.iiarjournals.org/content/41/4/2187.abstract N2 - Background/Aim: The present study aimed to examine the therapeutic efficacy of ramucirumab compared with that of sorafenib as subsequent systemic therapy for patients with hepatocellular carcinoma (HCC) and serum α-fetoprotein (AFP) levels ≥400 ng/ml. Patients and Methods: In our prospectively registered, real-world cohort, 13 and 11 patients treated with ramucirumab or sorafenib, respectively, were analyzed. Progression-free survival (PFS) was primarily compared between the ramucirumab and sorafenib groups. Results: The PFS was significantly longer in the ramucirumab group than in the sorafenib group (median, 2.7 vs. 0.9 months, respectively; p=0.005). There were no significant differences in the objective response rates or the disease control rates between the ramucirumab and sorafenib groups (9.1% and 54.5% vs. 0.0% and 22.2%, respectively). Conclusion: Subsequent systemic therapy with ramucirumab showed a better ability to control tumor progression than sorafenib in HCC patients with serum AFP levels ≥400 ng/ml. ER -